Michael H. Mulroy
Board of Directors
Business and Management
Unique Deliveries LLC
Canada
Biography
Michael H. Mulroy currently serves as President and Chief Executive Officer of of Asterias Biotherapeutics (NYSE MKT: AST), which was a subsidiary of AgeX parent company BioTime, Inc. until its deconsolidation from BioTime in May 2016. Prior to joining Asterias in June 2017, Mr. Mulroy served as a Senior Advisor to CamberView Partners, LLC, which assists companies in connection with investor engagement and complex corporate governance issues. Mr. Mulroy served until September 2014 as Executive Vice President – Strategic Affairs and General Counsel of the Autoimmune and Rare Diseases Business Unit of Mallinckrodt plc following its acquisition of Questcor Pharmaceuticals, Inc. in August 2014. Mr. Mulroy was appointed Executive Vice President, Strategic Affairs and General Counsel and Corporate Secretary of Questcor in February 2014, having previously served as Chief Financial Officer, General Counsel and Corporate Secretary since 2011. From 2003 to 2011, Mr. Mulroy was with the law firm of Stradling Yocca Carlson & Rauth, where he served as a partner from 2004, representing Questcor and other publicly-traded companies. From 1997 to 2003, Mr. Mulroy was an investment banker at Citigroup and Merrill Lynch. Mr. Mulroy currently serves on the Board of Directors of Asterias Biotherapeutics, Inc. and BioTime, Inc. Mr. Mulroy earned his J.D. degree from the University of California, Los Angeles, and his B.A. (Economics) from the University of Chicago.
Research Interest
Business and Management
